NVAX.US Novavax Inc

Healthcare Biotechnology USA Stocks
8.06 USD
Close of Nov 17, 2026
6.20 13.39
Market cap
USD 1.33B
P/E
-
P/B
41.23x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NVAX.US undervalued?

Graham number

The Graham number of Novavax Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novavax Inc fundamental analysis

No fundamental analysis for Novavax Inc yet.

Novavax Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novavax Inc

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, a…

Full company profile